New Lows: ArQule, Inc. (NASDAQ:ARQL), AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO), Tetralogic Pharmaceuticals Corp (NASDAQ:TLOG), TrovaGene Inc (NASDAQ:TROV)

ArQule, Inc (NASDAQ:ARQL) CEO Paolo Pucci purchased 5,000 shares of the company’s stock in a transaction dated Tuesday, May 20th. The stock was purchased at an average cost of $1.42 per share, with a total value of $7,100.00. Following the transaction, the chief executive officer now directly owns 232,280 shares of the company’s stock, valued at approximately $329,838. ArQule, Inc. (NASDAQ:ARQL) stock performance was -2.76% … Continue reading New Lows: ArQule, Inc. (NASDAQ:ARQL), AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO), Tetralogic Pharmaceuticals Corp (NASDAQ:TLOG), TrovaGene Inc (NASDAQ:TROV)

Biotech Losers: PTC Therapeutics (NASDAQ:PTCT), Prosensa Holding (NASDAQ:RNA), Concert Pharmaceuticals Inc (NASDAQ:CNCE), Tetralogic Pharmaceuticals Corp (NASDAQ:TLOG), Agios Pharmaceuticals Inc (NASDAQ:AGIO)

One solution, developed by PTC Therapeutics Inc. (NASDAQ:PTCT), a US biotechnology company, is to intervene in the transcription process in which the DNA is converted first to messenger RNA and then into protein. PTC Therapeutics Inc. (NASDAQ:PTCT)’s experimental drug ataluren is designed to override the false stop signal by interacting with the ribosome – the tiny biological machine inside every cell that runs along messenger … Continue reading Biotech Losers: PTC Therapeutics (NASDAQ:PTCT), Prosensa Holding (NASDAQ:RNA), Concert Pharmaceuticals Inc (NASDAQ:CNCE), Tetralogic Pharmaceuticals Corp (NASDAQ:TLOG), Agios Pharmaceuticals Inc (NASDAQ:AGIO)

Biotech New Lows: AVEO Pharmaceuticals (NASDAQ:AVEO), Onconova Therapeutics (NASDAQ:ONTX), BioTime (NYSEMKT:BTX), Tetralogic Pharmaceuticals (NASDAQ:TLOG)

FDA publicly (justifiably) took down AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) when patients on its drug survived less long than those in the control group. Novo Nordisk found itself years behind competitors because the FDA insists on a heart safety study of its new insulin. AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) stock performance was -3.21% in last session and finished the day at $1.51. Traded volume was 730,784.00million shares … Continue reading Biotech New Lows: AVEO Pharmaceuticals (NASDAQ:AVEO), Onconova Therapeutics (NASDAQ:ONTX), BioTime (NYSEMKT:BTX), Tetralogic Pharmaceuticals (NASDAQ:TLOG)

Biotech New Lows: Akebia Therapeutics (NASDAQ:AKBA), Galmed Pharmaceuticals (NASDAQ:GLMD), Tetralogic Pharmaceuticals (NASDAQ:TLOG), Dipexium Pharmaceuticals (NASDAQ:DPRX)

Akebia Therapeutics Inc. (NASDAQ:AKBA) offered 5.9 million shares in its Thursday IPO at $17 a share, the high end of the stock’s expected price range. Among other therapeutics, the biopharma company is developing a once-daily oral therapy for patients with kidney disease. Akebia Therapeutics, Inc. (NASDAQ:AKBA) stock performance was -0.99% in last session and finished the day at $20.00. Traded volume was 219,904 million shares … Continue reading Biotech New Lows: Akebia Therapeutics (NASDAQ:AKBA), Galmed Pharmaceuticals (NASDAQ:GLMD), Tetralogic Pharmaceuticals (NASDAQ:TLOG), Dipexium Pharmaceuticals (NASDAQ:DPRX)

Biotech New Lows: VIVUS (NASDAQ:VVUS), Dipexium Pharmaceuticals (NASDAQ:DPRX), Tetralogic Pharmaceuticals (NASDAQ:TLOG), Galmed Pharmaceuticals (NASDAQ:GLMD)

VIVUS, Inc. (NASDAQ:VVUS) announced that Shari Belafonte is teaming up with the company to educate American adults about seeking medical treatment for chronic weight management when diet and physical activity alone have not been successful. Ms. Belafonte, an actress, model, photographer, writer, singer and daughter of famed musician and actor Harry Belafonte, knows that the impact of being overweight is more than superficial. VIVUS, Inc. … Continue reading Biotech New Lows: VIVUS (NASDAQ:VVUS), Dipexium Pharmaceuticals (NASDAQ:DPRX), Tetralogic Pharmaceuticals (NASDAQ:TLOG), Galmed Pharmaceuticals (NASDAQ:GLMD)